Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 8/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489954 | 1.00 | FGFR3 (0.45) | FGFR3FGFR1FGFR4FGFR2KCNH2 | |
| SCHEMBL18131765 | 0.83 | FGFR1 (0.45) | FGFR3FGFR1FGFR4FGFR2KCNH2 | |
| SCHEMBL22807283 | 0.83 | FGFR3 (0.45) | FGFR3FGFR1FGFR4FGFR2KCNH2 | |
| SCHEMBL21280305 | 0.78 | FGFR3 (0.50) | FGFR3FGFR1FGFR4FGFR2KCNH2 | |
| SCHEMBL15244132 | 0.78 | FGFR3 (0.50) | FGFR3FGFR1FGFR4FGFR2KCNH2 | |
| SCHEMBL22807293 | 0.76 | FGFR1 (0.60) | FGFR3FGFR1FGFR4FGFR2CYP3A4 | |
| SCHEMBL28696599 | 0.76 | FGFR1 (0.47) | FGFR3FGFR1FGFR4FGFR2KCNH2 | |
| SCHEMBL21386636 | 0.75 | FGFR3 (0.57) | FGFR3FGFR1FGFR4FGFR2KCNH2 | |
| SCHEMBL15633170 | 0.72 | APP (0.54) | — | |
| SCHEMBL21280290 | 0.72 | FGFR3 (0.61) | FGFR3FGFR1FGFR4FGFR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362245-A1 | COMPOUNDS FOR INHIBITING FGFR4 | TERNS PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3986405-A1 | COMPOUNDS FOR INHIBITING FGFR4 | Terns Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114144176-A | Compounds for inhibiting FGFR4 | 拓臻制药公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2020257527-A1 | COMPOUNDS FOR INHIBITING FGFR4 | Terns, Inc. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362245-A1 | COMPOUNDS FOR INHIBITING FGFR4 | FGFR4, FGFR1, FGFR3 | FGFR3 3/4885FGFR1 2/4885FGFR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.